Division of Nephrology, Children's Hospital of Philadelphia, 3401 Civic Center Boulevard, Philadelphia, PA, 19104, USA.
Department of Pediatrics, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA.
Pediatr Nephrol. 2021 Sep;36(9):2639-2658. doi: 10.1007/s00467-020-04869-w. Epub 2021 Jan 21.
Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) are characterized by bilateral cystic kidney disease leading to progressive kidney function decline. These diseases also have distinct liver manifestations. The range of clinical presentation and severity of both ADPKD and ARPKD is much wider than was once recognized. Pediatric and adult nephrologists are likely to care for individuals with both diseases in their lifetimes. This article will review genetic, clinical, and imaging predictors of kidney and liver disease progression in ADPKD and ARPKD and will briefly summarize pharmacologic therapies to prevent progression.
常染色体显性遗传性多囊肾病(ADPKD)和常染色体隐性遗传性多囊肾病(ARPKD)的特征是双侧囊性肾病导致进行性肾功能下降。这些疾病也有明显的肝脏表现。与以往认识相比,ADPKD 和 ARPKD 的临床表现范围和严重程度要广泛得多。儿科和成人肾脏病医生在其一生中都可能会照顾到患有这两种疾病的个体。本文将回顾 ADPKD 和 ARPKD 中肾脏和肝脏疾病进展的遗传、临床和影像学预测因素,并简要总结预防疾病进展的药物治疗方法。